Literature DB >> 29269527

Risk of progression of monoclonal gammopathy of undetermined significance into lymphoplasmacytic malignancies: determining demographic differences in the USA.

Ronald S Go1,2, Herbert C Heien2, Lindsey R Sangaralingham2, Elizabeth B Habermann2, Nilay D Shah2.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29269527      PMCID： PMC5830389          DOI： 10.3324/haematol.2017.179978

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.

Authors:  Ola Landgren; Gloria Gridley; Ingemar Turesson; Neil E Caporaso; Lynn R Goldin; Dalsu Baris; Thomas R Fears; Robert N Hoover; Martha S Linet
Journal:  Blood       Date:  2005-10-06       Impact factor: 22.113

2.  Long-term follow-up of a population based cohort with monoclonal proteinaemia.

Authors:  Cees G Schaar; Saskia le Cessie; Simone Snijder; Paul F H Franck; Pierre W Wijermans; Cisca Ong; Hanneke Kluin-Nelemans
Journal:  Br J Haematol       Date:  2008-11-19       Impact factor: 6.998

3.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

4.  Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey.

Authors:  O Landgren; B I Graubard; J A Katzmann; R A Kyle; I Ahmadizadeh; R Clark; S K Kumar; A Dispenzieri; A J Greenberg; T M Therneau; L J Melton; N Caporaso; N Korde; M Roschewski; R Costello; G M McQuillan; S V Rajkumar
Journal:  Leukemia       Date:  2014-01-20       Impact factor: 11.528

5.  Survival of cancer patients with prior monoclonal gammopathy of undetermined significance.

Authors:  Henrik Gregersen; Henrik Toft Sørensen; Malene Cramer Engebjerg; Paw Jensen; Marianne Tang Severinsen; Mette Nørgaard
Journal:  Eur J Intern Med       Date:  2010-09-19       Impact factor: 4.487

6.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

7.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

8.  Monoclonal gammopathy in Iceland: a population-based registry and follow-up.

Authors:  Helga M Ogmundsdóttir; Vilhelmína Haraldsdóttir; Guethmundur M Jóhannesson; Guethríethur Olafsdóttir; Kristín Bjarnadóttir; Helgi Sigvaldason; Hrafn Tulinius
Journal:  Br J Haematol       Date:  2002-07       Impact factor: 6.998

9.  Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition.

Authors:  Terry M Therneau; Robert A Kyle; L Joseph Melton; Dirk R Larson; Joanne T Benson; Colin L Colby; Angela Dispenzieri; Shaji Kumar; Jerry A Katzmann; James R Cerhan; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2012-08-07       Impact factor: 7.616

10.  Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden.

Authors:  Ingemar Turesson; Stephanie A Kovalchik; Ruth M Pfeiffer; Sigurdur Y Kristinsson; Lynn R Goldin; Mark T Drayson; Ola Landgren
Journal:  Blood       Date:  2013-11-12       Impact factor: 22.113
View more
  3 in total

Review 1.  How I manage monoclonal gammopathy of undetermined significance.

Authors:  Ronald S Go; S Vincent Rajkumar
Journal:  Blood       Date:  2017-11-28       Impact factor: 22.113

2.  Educational intervention to optimise serum immunoglobulin test use in Irish primary care: an interrupted time series with segmented regression analysis.

Authors:  Sharon L Cadogan; John P Browne; Colin P Bradley; Anthony P Fitzgerald; Mary R Cahill
Journal:  Br J Gen Pract       Date:  2020-01-30       Impact factor: 5.386

3.  A Single-Center Retrospective Study to Investigate the Follow-Up of Patients with Monoclonal Proteinemia by Community Physicians in the UK.

Authors:  Indra Ramasamy
Journal:  J Blood Med       Date:  2020-06-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.